BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy

Reuters

03 Apr

BRIEF-Intellia <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy

April 3 (Reuters) - Intellia Therapeutics Inc NTLA.O:

INTELLIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE MAGNITUDE-2 PHASE 3 STUDY OF NEXIGURAN ZICLUMERAN (NEX-Z), A ONE-TIME GENE EDITING-BASED TREATMENT FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY
INTELLIA THERAPEUTICS INC: PLANS TO SUBMIT A BIOLOGICS LICENSING APPLICATION FOR ATTRV-PN BY 2028

Source text: ID:nGNX1L2QP0

Further company coverage: NTLA.O

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2524253667"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524253667\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524253667?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 19:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524253667","market":"us","top_or_hot":-1,"title":"BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Intellia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy</title></head><body><p><span>April 3 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/NTLA\">Intellia Therapeutics Inc</a> <span>NTLA.O</span>:</p><ul><li><p>INTELLIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE MAGNITUDE-2 PHASE 3 STUDY OF NEXIGURAN ZICLUMERAN (NEX-Z), A ONE-TIME GENE EDITING-BASED TREATMENT FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY</p></li><li><p>INTELLIA THERAPEUTICS INC:  PLANS TO SUBMIT A BIOLOGICS LICENSING APPLICATION FOR ATTRV-PN BY 2028</p></li></ul><p>Source text: <span>ID:nGNX1L2QP0</span></p><p>Further company coverage: <span>NTLA.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-03 19:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Intellia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy</title></head><body><p><span>April 3 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/NTLA\">Intellia Therapeutics Inc</a> <span>NTLA.O</span>:</p><ul><li><p>INTELLIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE MAGNITUDE-2 PHASE 3 STUDY OF NEXIGURAN ZICLUMERAN (NEX-Z), A ONE-TIME GENE EDITING-BASED TREATMENT FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY</p></li><li><p>INTELLIA THERAPEUTICS INC:  PLANS TO SUBMIT A BIOLOGICS LICENSING APPLICATION FOR ATTRV-PN BY 2028</p></li></ul><p>Source text: <span>ID:nGNX1L2QP0</span></p><p>Further company coverage: <span>NTLA.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0DE:1","article_id":"2524253667","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524253667","pubTimestamp":1743680133,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With PolyneuropathyApril 3 (Re","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-Intellia Therapeutics宣布Nexiguran Ziclumeran(Nex-Z)治疗甲状腺素运载蛋白(Attr)淀粉样变性伴多发性神经病的Magnitude-2期3期研究中首例患者接受给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":0.9},"content_text":"BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With PolyneuropathyApril 3 (Reuters) - Intellia Therapeutics Inc NTLA.O:INTELLIA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE MAGNITUDE-2 PHASE 3 STUDY OF NEXIGURAN ZICLUMERAN (NEX-Z), A ONE-TIME GENE EDITING-BASED TREATMENT FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHYINTELLIA THERAPEUTICS INC:  PLANS TO SUBMIT A BIOLOGICS LICENSING APPLICATION FOR ATTRV-PN BY 2028Source text: ID:nGNX1L2QP0Further company coverage: NTLA.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1}}}